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ABSTRACT 
Background: In Gauteng Province, South Africa, Sizwe Tropical Hospital (STH) 
is the designated centre for the specialized management of MDR-TB. But during 
the period covered by this study (2001-2002), all cases of TB (MDR-TB and 
NMDR-TB) were treated at STH. This was not according to the prescript of the 
National guidelines. This study describes the socio-demographic, treatment 
profile and treatment outcomes of MDR-TB patients seen and treated at STH 
during 2001 and 2002. 
 
Method: This was a cross sectional study involving retrospective review of 
records at STH. 281 systematically-sampled MDR-TB patient records were 
included in this study. Descriptive statistics were used to summarize the socio-
demographic and treatment history characteristics and these were further 
analyzed to evaluate their relationship with MDR-TB treatment outcomes using 
Chi squared test of association. Means were compared using simple t-test.  
 
Results: The patients were majority black, unemployed, and living in townships 
and informal settlements. Sputum tests alone or combined with x-ray were most 
commonly used to diagnose MDR-TB (98%) at referring facilities; and the 
majority of patients arrived at STH with a referral note (98%). The median 
duration of stay at STH was 56 weeks (IQR 21-89). The majority of patients had 
a successful treatment outcome (75%); and amongst those with unsuccessful 
outcomes, a significant number had died (17%). Factors associated with poor 
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outcomes in terms of death, default, treatment failure and transfer out were age 
groups (1-9 and 30-39), race, employment status, place of residence, housing 
structure, referral systems (referral note and feedback procedures) and HIV 
status. 
Discussion: The patients in this study had socio-demographic characteristics 
that facilitate TB transmission. There is a commendable referral system but 
various methods used to confirm MDR-TB and unjustified long duration of 
treatment prior to referral.  
 
Although in general the majority of patients have successful treatment outcomes, 
the policy guidelines of the management of MDR-TB are not implemented fully, 
and several factors associated to poor outcome are related to the health service 
and referral system. 
 
Recommendation: Effective adherence to the policy guidelines by health care 
providers and patients is recommended to improve treatment outcomes.  
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CHAPTER 1: INTRODUCTION 
1.1 Background 
Tuberculosis (TB) is a critical public health problem globally. It is the leading cause of 
death among curable infectious diseases. The International Union Against TB and Lung 
Diseases (IUATLD) reports that Mycobacterium tuberculosis, the microbe that causes 
TB, is responsible for about 8.8 million cases of TB and nearly 2 million TB deaths each 
year, most of them in low-income countries (IUATLD, 2009).  
Generally, the main reasons for the increasing global TB burden include: poverty and 
the widening gap between the rich and poor in various populations; poor program 
management in terms of inadequate case detection, diagnosis and cure; the impact of 
the Human Immuno-deficiency Virus (HIV) pandemic; and the collapse of infrastructure 
in countries experiencing deep economic crises or civil unrest. (National Department of 
Health [NDoH], 2004).  
Multi drug-resistant TB (MDR-TB), a disease caused by Mycobacterium tuberculosis 
strains that are resistant to at least Rifampicin and Isoniazid, is a serious global public 
health problem because it entails extended treatment, expensive and toxic regimens, 
and reflects higher rates of treatment failure and death (Chan et al., 2004). In 2004 it 
was reported that the global number of incidence cases of MDR-TB of all new and 
previously treated TB cases nearly doubled from 2000 (272,906) to 2004 (424,203) 
(Zignol et al., 2006). In the same year (2004), a total of 181,408 MDR-TB cases were 
estimated to have occurred among previously treated TB cases alone (Zignol et al., 
2006).  
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In 2008, there were 29,423 MDR-TB cases reported throughout the world by 127 
countries. These cases only represent about seven percent of the MDR-TB cases 
estimated to have emerged that year (WHO, 2010). In South Africa, a country with a 
high burden of TB, a high prevalence of HIV and Acquired Immuno-deficiency 
Syndrome (AIDS) co-infection rate, HIV/AIDS has further exacerbated MDR-TB. The 
number of laboratory confirmed cases of MDR-TB more than tripled from 2,000 in 2005 
to 7,350 in 2007 (WHO, 2008). Furthermore, South Africa has seen an increasing 
number of reported patients with XDR-TB since 2007 (from 74 cases in 2004 to 536 in 
2007) (NDoH, 2008). 
It is recommended that the best way to control MDR-TB is to ensure effective control of 
TB. The National Tuberculosis Control Program (NTBCP) guidelines in South Africa 
recommend the following strategies for TB control (NDOH, 2004): 
1) The integration of services for TB control into primary health care (PHC) to 
ensure its effectiveness and its sustainability. At this first level, access to 
diagnosis and to TB treatment (using the DOTS system) should be made 
available to the population through strong community participation.  
2) The decentralization of the management of TB cases to the local facilities (clinics, 
SANTA or TB hospitals) to promote the DOT strategy. At that level sputum can 
be collected and sent to the nearest laboratory facility. Once the result is 
diagnosed as positive, treatment (first line) can be initiated at the same level. 
(SANTA stands for South African National Tuberculosis Association and had in 
the past years managed many TB hospitals. 
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3) The referral of TB complications to district, regional and tertiary hospitals.  
4) The transfer of all confirmed MDR-TB (sputum culture sensitive to at least both 
INH and RIF) to a specialized centre where trained staff will initiate standardized 
MDR-TB treatment.  
 
The 2004 South African National Tuberculosis control program guidelines (SANTBCPG) 
and the MDR-TB policy guidelines of June 2007 clearly outline the management of TB 
and TB associated conditions, including MDR-TB, XDR-TB (extremely or extensively 
drug resistant-TB) and TB complications in South Africa. These guidelines require that 
all MDR-TB and other complicated TB cases be referred to a specialized centre where 
they can be fully assessed and managed by experts. The policy guideline for the 
management of MDR-TB in Gauteng recommends a standardized treatment regimen 
for 4 months (initial intensive phase) followed by 12-18 months of the continuation 
phase. Individualized treatment is given based on the results of drug susceptibility tests 
(NDoH, 2007).  
 
Recently, the emergence of XDR-TB cases in the province has presented treatment 
challenges and highlighted why it is important to correctly and quickly diagnose and 
treat MDR-TB. In Gauteng Province of SA, in order to adhere to national policy, the 
Sizwe Tropical Hospital (STH), a 220 bed specialized hospital, was chosen to fulfill the 
role of a specialized MDR-TB treatment hospital. This is because of its past experience 
of being a tropical disease hospital, having isolation facilities and staff who are skilled 
and experienced to handle complicated cases, including MDR-TB. A specialized unit 
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was established at STH with the aim of evaluating the effectiveness of treating MDR-TB 
patients using a standardized regimen of second line anti-TB drugs and of monitoring 
the reduction of the burden and spread of multi-drug resistant.   
 
There are two main categories of TB that are managed at STH at present. The first 
category includes TB cases falling into the WHO definition of MDR-TB comprising the 
commonly called MDR-TB (established resistance to  both INH and RIF), poly resistant 
TB (laboratory confirmed resistance to INH, RIF and Ethambutol), high grade resistant 
TB (confirmed resistance to at least 4 first line anti-TB drugs) and XDR-TB (confirmed 
resistance to at least RIF and INH, in addition to any Fluoroquinolone, and at least one 
of the three following injectables drugs: Apreomycin, kanamycin and Amikacin).The 
second category includes non-MDR-TB (NMDR-TB) cases including all pulmonary TB, 
extra pulmonary TB, all TB complications such as TB meningitis, TB lymphadenitis, 
Miliary tuberculosis, TB pleural effusion, Tuberculous Empyema, Tuberculous 
pericardial effusion, Ascitis, TB of the bones as well as all cases of drug resistance not 
falling into the WHO definition of MDR-TB. The correct procedures for diagnosis and 
treatment of these conditions are reflected in the SA national policy guidelines; and it is 
essential to adhere to these guidelines to ensure effective TB control (NDoH, 2007). 
 
The NTBCP recommendations have been adopted by the TB program in Gauteng. The 
control of TB in Gauteng has however been a challenge. The TB co-ordination team 
that has been set up at provincial level to oversee TB control has experienced 
challenges in each of the following steps in the control of TB: correct diagnostic process 
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at health facilities (a positive sputum result is diagnostic); starting first line TB treatment 
as early as possible, supported by the DOT strategy; and the monitoring of treatment 
progress by monthly sputum tests. There have also been challenges in referral and 
management of MDR-TB (NDoH, 2004). 
 
At STH, all cases are admitted in the program through the gate way clinic which is a 
triage facility within the hospital. After being seen by dedicated doctors and staff, critical 
patients are admitted into hospital wards and less serious ones followed in ambulatory 
care or sent back to the referring facility with a management guide. Those who are 
admitted will have one of the following outcomes: cured, these will be sent to the 
referring facility with a specific follow up treatment plan; died these will be discharged to 
the undertaker. Some will default treatment, will be transfer out or will fail treatment. 
Nevertheless there was no appropriately written operational discharge policy at that 
time.   
 
1.2 Problem statement 
The management of MDR-TB is one of the most critical public health issues today, 
especially in the context of the fast-growing HIV and AIDS epidemic and the emergence 
of a new resistant strain of TB, the XDR-TB (WHO, 2010). In Gauteng, at the time of the 
implementation of the TB electronic register, annual reports demonstrated that there 
were 27453 and 31784 cases of TB reported in 2001 and 2002, respectively. During this 
period MDR-TB data was not being collated. But statistics from STH show that there 
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were 446 and 400 cases of MDR-TB in 2001 and 2002 respectively (Gauteng 
Department of Health (GDoH), 2001; GDoH, 2002). 
In Gauteng, proper routine data collection for MDR-TB cases only started in March 2003 
and by 2008 the electronic register for MDR-TB was not yet developed. Many questions 
arose about what was happening at STH with the implementation of the national policy 
guidelines on TB and MDR-TB. These questions include:  
a) Who were the patients who were referred to STH for MDR-TB treatment? 
b) Were the patients on MDR-TB treatment were indeed confirmed MDR-TB cases 
(based on WHO definition of MDR-TB); 
c) Were clinicians at health facilities (facilities where MDR-TB diagnosis was made) 
adhering to the guidelines for diagnosis, referral and the management of MDR?  
d) How were patients managed, and what were their treatment outcomes at STH?   
 
This study addresses these questions, with a focus on STH. The study which covers the 
period from 2001 to 2002, describes the demographic and socio-economic profile of 
MDR-TB patients admitted at STH during this period, the processes for their diagnosis 
and referral to STH, and their MDR-TB treatment characteristics, and treatment 
outcomes. 
 
1.3 Justification for the study 
This study explores the way in which national TB guidelines for MDR-TB have been 
implemented in Gauteng by identifying how MDR patients are diagnosed and managed 
(i.e. their route through the health system from referral facility to STH). This will help in 
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identifying gaps in management of MDR-TB, and identify whether there is proper 
adherence to MDR-TB guidelines. The study is also useful for the provincial TB program 
in other ways. By providing information on the performance of the MDR-TB treatment 
program at STH, the study findings can assist TB control program managers with 
planning and program management, and assist clinicians to improve treatment of MDR-
TB patients at STH. By trying to determine the treatment outcomes of patients with 
confirmed MDR-TB, this study provides baseline data that could be used for future 
monitoring. This is further important since no similar study has been done. Finally, this 
being a descriptive study, it raises issues that can be investigated further in other 
analytical studies. 
 
1.4 Literature review. 
The following issues are considered in the literature review: the burden of the disease; 
adherence to policy guidelines in managing TB and the importance for TB control; 
determinants of treatment outcomes; experiences with managing MDR-TB in various 
settings; and outcomes of MDR-TB treatment. As a point of clarification preference has 
been first given to more recent publications (2005-2010). Publications before 2005 were 
considered for review only in cases where more recent articles were not available to 
illustrate specific issues specially referring to the South African publications going as far 
as 1997. 
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1.4.1 Burden of TB 
Tuberculosis (TB) is still a major global health problem today despite treatment having 
been available for over 50 years. Furthermore, TB remains a serious public health 
challenge and is the leading cause of death in people living with AIDS, as well as the 
most important infectious disease causing death in all ages in the general population 
(IUATLD, 2009). In 2008 WHO reported an estimate of 9.4 million incident cases of TB, 
11.1 million prevalent cases of TB, 1.3 million deaths among HIV negative TB patients 
and 0.52 million deaths among HIV positive TB patients (WHO, 2008).  Recently 
Multidrug-resistant -tuberculosis (MDR-TB) has emerged as a global epidemic, with 
425,000 new cases estimated to occur annually (Wells et al., 2007).  The WHO has 
released a new report on anti-TB extensively drug resistant TB (M/XDR-TB) stating that 
in 2008, an estimated 440 000 cases of MDR-TB emerged globally with 150 000 
deaths. (WHO, 2010)        
 
The emergences of MDR-TB and thereafter of XDR-TB are the most critical aspect of 
the TB epidemic in South Africa (SA). WHO declared SA to have one of the worst 
recorded TB epidemics in the world due to the high TB rate, the rise of HIV, and the 
emergence of MDR-TB. According to a 2009 WHO report, among the twenty two 
countries classified with the highest TB burden globally, eight are in Africa and SA is 
ranked fifth with 948 cases per 100 000 population, a major increase from 338 cases 
per 100 000 population in 1998 (WHO/IUATLD, 2009). A drug resistance survey found 
that in South Africa, about 1.6% of new TB cases and about 6.7% of previously treated 
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cases were MDR-TB. This translates into at least 6000 new cases of MDR-TB in SA 
each year (Blumberg, 2003).  
 
The need to address the problem of TB and MDR-TB in SA became urgent since the 
emergence of the epidemics of XDR-TB cases in KZN Tugela Ferry. Dr Friedland of 
FIDSA indicated that generally, 50% of patients newly infected with HIV in sub-Saharan 
Africa are also TB infected; but in Tugela Ferry 90 % of these HIV infected are co-
infected with TB. The TB case rate is more than 1000 per 100 000 people. By the end of 
2009, nearly 1000 cases of XDR-TB and MDR-TB had been diagnosed, with more than 
a half being XDR-TB (IDSA News-Nov. /Dec. 2010). 
 
1.4.2 Guidelines for TB control 
It is critical to acknowledge that poor TB management will facilitate the development of 
MDR-TB, and also to recognize that MDR-TB is a threat to TB control (Prasad, 2007). 
Generally, prevention and control of MDR-TB is obtained through implementation of a 
good TB control program operating under the DOTS strategy (Yew & Leung., 2008; 
Blöndal., 2007). 
 
In 1991, the 44th World Health Assembly set two key targets for global TB control to be 
reached by 2000: 70% case detection of acid-fast bacilli smear-positive TB patients 
under the DOTS strategy recommended by WHO and 85% treatment success of those 
detected to be smear-positive (Laserson and Wells. 2007). WHO, in support of 
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countries affected with the TB epidemic, has developed policy guidelines to help these 
countries to achieve efficient and effective management of TB and MDR-TB.  
 
South Africa has implemented WHO guidelines in the form of practical guidelines which 
have outlined how TB and MD R-TB should be diagnosed and managed. The guidelines 
indicate clearly that the treatment of smear- positive patients is the most important way 
to control TB and prevent complications, and MDR-TB. The guidelines also state that 
sputum testing is the appropriate method for making a diagnosis of TB, and that too 
much reliance on chest X-ray in the diagnosis of TB results in unnecessary treatment, 
because chest X-ray is not a reliable predictor of active TB (DoH, 2004). The guidelines 
insist that TB culture for drug susceptibility testing is done on all patients who continue 
to have positive sputum smears in spite of correct treatment. In this way, MDR-TB can 
be detected early and appropriate treatment started. 
 
1.4.3 MDR-TB treatment outcomes  
The following are commonly recorded outcomes of TB treatment: successful treatment 
(cure), relapse, failure, transfer out, death, default or loss during follow up (Palmero et 
al., 2004). Successful outcomes will also include treatment completion, sputum 
conversion, disappearance of X-ray lesions; while relapse, failure, transfer out, death, 
default (loss during follow up), remain on treatment, referred to surgery constitute what 
is also called unsuccessful outcomes (Masjedi et al., 2008; Laserson et al., 2005; 
Shean et al., 2008; Dhingra et al., 2008).  
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Treatment outcomes are often unsuccessful in multidrug-resistant (MDR) and 
extensively drug-resistant (XDR) tuberculosis (TB), and successful outcomes are 
generally low (Shean et al., 2008). Experience with MDR-TB treatment outcomes varies 
in different settings. For example, a descriptive study conducted in 1996 in Santa Cruz, 
Bolivia revealed that a successful outcome was achieved in 28% of patients, while 48% 
defaulted, and 13% died and 10% were still under treatment (Olle-Goig & Sandy, 2005). 
Another study by Tupaisi et al (2003) in the Phillipines showed a cure rate of 73.4%, a 
failure rate of 3.8% and a likely failure rate of 6.3%; while death occurred in 3.8% and 
defaulting was observed in 11.4 %). 
 
Latvia has one of the highest rates of MDR-TB in the world. In a study conducted there 
to assess treatment outcomes for the first full cohort of MDR-TB patients treated under 
Latvia 's DOTS-Plus strategy following WHO guidelines, it was demonstrated that of the 
204 patients assessed, 55 (27%) had been newly diagnosed with MDR-TB, and 149 
(73%) had earlier been treated with first-line or second-line drugs for this disease. 
Assessment of treatment outcomes showed that 135 (66%) patients were cured or had 
completed therapy, 14 (7%) had died, 26 (13%) had defaulted, and 29 (14%) had 
treatment failure. Of the 178 adherent patients, 135 (76%) achieved a cure or treatment 
completion which is an example of a good outcome (Leimane et al., 2005). 
 
1.4.4   Determinants of MDR-TB treatment outcome   
According to literature TB treatment outcomes are influenced directly or indirectly by a 
number of factors, including: socio-demographic characteristics (age, sex, education 
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level and economic status), treatment delay, inappropriate prior TB treatment with poor 
adherence (inefficient DOTS strategy and referral system), poor prescription and 
provision of drugs, staffs‘ bad attitude, the HIV sero-positive status, previous TB 
treatment for more than 4 weeks, smoking (for Isoniazid resistance), the presence of 
cavitations on the chest radiograph, and imprisonment (Ekaterina et al., 2006). 
 
a) Socio-demographic factors  
There are very few studies that have looked at the socio-demographic characteristics of 
TB and MDR-TB patients in international literature and especially in South Africa. The 
following are the most reported socio-demographic characteristics of TB and MDR-TB 
patients in the literature: age group, sex, race, employment status, area of residence 
and housing (DoH, 2004; Amin et al., 2009). For instance in Abidjan, Ivory Coast, 
among MDR-TB patients, those aged 20-40 years are the most commonly-affected 
group (72%), with a clear male predominance (sex ratio 3:1), and most of them living in 
dwellings with a common yard (Kouassi et al., 2004). Furthermore, a South African 
study by Rawlinson et al (2000) on MDR-TB explains that unemployment is a 
contributing factor leading to poverty, which is an important social determinant of TB 
and MDR-TB (Rawlison et al., 2000). 
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b) Previous TB treatment  
Prior ineffective treatment is a strong predictor of drug resistance (Espinal et al, 2001). It 
has been shown that the high rates of MDR-TB are associated with previous anti-
tuberculosis treatment, and that the chance of developing MDR-TB is significantly 
increased when inadequate TB treatment is given for more than three months 
(Mendoza et al., 1997). Other factors to consider in relation to previous treatment are 
the effectiveness of the treatment, the duration of treatment, the delay in starting 
treatment, the outcome of that treatment (e.g. previous treatment failure), and multiple 
previous TB episodes ( Espinal et al., 2001).  
 
c) Clinical and treatment features 
Delay in starting appropriate MDR-TB treatment after the diagnosis has been made also 
has potentially serious consequences, and increases the risk of developing MDR. 
Predictors of good outcomes regarding treatment include: resistance to not more than 
three anti-tubercular drugs, use of less than or up to three second line drugs in 
treatment, and no change of regimen during treatment ( Dhingra et al., 2008). Predictors 
of poor outcomes include: previous treatment for MDR-TB, the use of five or fewer 
drugs for three months or more, and resistance to ofloxacin (Leimane et al., 2005) 
 
Clinical features such as cavities present on chest X-rays are factors associated with 
MDR-TB development, and are high risk mostly in low-income countries (Temple et al., 
2008). A body mass index of less than 18.5 at the start of treatment is also associated 
with MDR-TB development (Leimane et al., 2005). Clinical predictors of good MDR-TB 
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treatment outcome include: weight gain at six months of treatment, culture conversion, 
and radiologic improvement during treatment (Dhingra et al., 2008).  
 
d) HIV/AIDS  
HIV infection is one of the most common determinants of poor TB/MDR-TB outcomes 
(Kliiman & Altraja, 2009). The global HIV epidemic is associated with significant 
increases in TB incidence and may be contributing to increases in MDR-TB (IUATLD, 
2009). Institutional outbreaks of MDR-TB have primarily affected HIV-infected persons. 
Delayed diagnosis of TB, inadequate initial TB treatment, and prolonged periods of 
infectiousness with TB have led to extraordinary TB attack rates and case-fatality rates 
among HIV-infected persons. HIV infection is also associated with mal absorption of 
anti-TB drugs and acquired Rifampicin resistance. HIV-infected patients with MDR-TB 
have high mortality rate; both antiretroviral and anti mycobacterial treatment are 
necessary (Wells et al., 2007). 
 
A study of patients in HIV prevalent areas of sub-Saharan Africa reveals that with a 
mere 0.7 % percent of the world‘s population, South Africa is home to 19 percent of 
human immunodeficiency virus (HIV) and tuberculosis co-infected people, the highest 
co-infection rate in the world. The rest of Africa accounts for 61 percent of global co-
infected patients. Furthermore this same study also found that the risk of tuberculosis 
was 8.3 times higher for those who were infected with HIV than for those who were HIV 
negative (Corbert et al., 2006). 
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It is projected that HIV/AIDS will delay the global control of the TB epidemic over the 
next few years (ref). Globally it is estimated that 73% of new TB patients are co-infected 
with HIV; and an estimated 31% of all TB-HIV cases in Africa are in SA (WHO, 2008). 
Churchyard et al (2000) revealed that the HIV epidemic has lead to increased TB 
incidence in South African miners. Very few studies have found no relationship between 
HIV and MDR-TB. One example is the study in the Ivory Coast which showed No link 
between HIV infection and MDR--TB. (Kouassi et al., 2004). 
 
But in general, the HIV and MDR-TB relationship is strongly supported in literature, and 
confirms that strong TB control - in particular, to ensure control of drug-resistant TB - 
will be facilitated by scaling-up WHO-recommended TB/HIV collaborative activities such 
as HIV counseling and testing of all TB patients, greater use and acceptance of 
Isoniazid as a preventive treatment in HIV-infected individuals, screening for active TB 
in HIV-care settings, and provision of universal access to antiretroviral treatment for all 
HIV-infected individuals eligible for such treatment; and by improving coordination 
between HIV and TB control programmes (Laserson and Wells, 2007) 
 
A retrospective cohort study by Dheda et al. (2010) investigating the association 
between HIV and XDR-TB in Kwazulu-Natal (KZN) suggested that, contrary to the 
findings of earlier studies in KZN (during 2006-2009) which suggested that XDR-TB in 
SA was predominantly associated with HIV infection, a majority (53%) of South African 
XDR-TB patients outside KZN province are HIV negative. The same study also shows 
that the number of deaths among HIV positive and HIV negative patients was not 
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significantly different, patients with XDR-TB have poorer management outcomes 
regardless of their HIV status, and sputum-culture conversion was not found to be 
associated with sex, ethnic group, or the numbers of previous episodes of MDR-TB. 
However low body weight (< 50 kg) before treatment was associated with conversion 
failure.  
 In summary, various studies have shown that MDR-TB is a serious public health 
problem. It has also been demonstrated that socio-demographic characteristics and 
treatment profile including HIV positivity are important determinants in acquiring MDR-
TB and attaining MDR-TB treatment outcomes. Understanding these characteristics of 
MDR-TB patients at STH is thus an important first step in exploring the determinants of 
MDR-TB acquisition and treatment outcome in Gauteng. These few characteristics that 
have been described in this study will give a baseline on the profile of MDR-TB patients 
before and after admission at STH. 
 
1.5 Aim and objectives 
1.5.1 Aim 
The aim of this study is to describe the profile of MDR-TB patients treated at STH during 
2001-2002; and to determine their MDR-TB treatment outcomes, with a view to also to 
formulating recommendations based on the findings. In the context of this study, the 
word profile refers to the socio-demographic and treatment characteristics of these 
MDR-TB patients.  
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1.5.2 Objectives 
The objectives of this study were:  
a) To describe the socio-demographic characteristics of MDR-TB patients treated at 
STH during 2001 to 2002 
b) To describe their treatment history at the referring facility level (past medical history 
before admission at STH)  
c) To determine the HIV prevalence among these MDR-TB patients. 
d) To describe these MDR-TB patients‘ treatment history at Sizwe Tropical Hospital.  
e) To describe MDR-TB patients‘ treatment outcomes. 
f) To evaluate associations between socio-demographic and clinical factors with their 
treatment outcomes. 
 
1.6 Definition of terms used in the study 
Multi-Drug Resistant-Tuberculosis (MDR-TB) 
In this study, MDR-TB is defined as the disease caused by TB bacilli resistant to at least 
Isoniazid (H) and Rifampicin (R). Drug resistance is further classified into ―primary‖ or 
―acquired‖ according to the patient‘s history of previous tuberculosis treatment. 
 Primary resistance: Resistance in cultures from patients with no history of 
previous TB treatment. 
 Acquired resistance: Resistance in cultures from patients with one or more 
previous TB treatment episodes (totaling more than one month). 
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 Initial resistance: Drug resistance in new TB patients, allowing for undisclosed 
previous treatment, i.e. ―initial resistance‖ refers to primary and undisclosed 
acquired resistance. This rate may be up to twice the rate for true primary 
resistance and the term is preferred by some authors when dealing with 
population-based studies. 
 
Re-treatment case 
 A patient who has taken treatment for TB before and either relapsed, defaulted or had 
treatment failure. 
 
Smear negative Pulmonary Tuberculosis case  
 At least 2 sputum smears are negative for AFBs. Chest X-ray abnormalities are 
consistent with active TB. 
 
Smear-positive Pulmonary Tuberculosis case  
There are at least 2 sputum smears positive for AFBs or 1 sputum smear positive for 
AFBs and chest X-ray abnormalities consistent with active TB or culture positive TB, or 
1 sputum smear and clinically ill. 
 
Treatment standardized   
It is a recommended regimen for 4 months for the treatment of MDR-TB cases. It is 
comprised of Kanamycin, Pyrazinamide, Ethambutol (or Terizidone), Ofloxacin (or 
ciprofloxacin) and Ethionamide during the initial intensive phase. This phase is followed 
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by 12-18 months of Ethambutol, Ofloxacin and Ethionamide in the continuation phase. 
Cycloserine is used as Ethambutol replacement when resistance to Ethambutol is 
detected (Department of Health (DoH), 2004).  
 
Treatment Individualized  
Individualized treatment is given to MDR-TB patients based on the results of drug 
susceptibility tests. If drug susceptibility test results are not yet available, the TB 
treatment is to be delayed and patients are started on the standardized regimen while 
awaiting drug susceptibility results (Department of Health (DoH), 2004).  
 
Regimen 1 TB treatment 
This treatment, which is given to TB patients as fist line treatment, includes R, H and E 
and Z.  
 
Ajunction of surgical treatment 
In case of pneumothorax and empyema, intra costal drains are inserted and washing 
performed. Sometimes artificial desh is done to demolish the space between the two 
pleural layers so to avoid recurrence of pleural effusions and finally patient will be 
referred to other tertiary hospitals for major procedures like lobectomies or 
pneumectomies. 
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CHAPTER 2: MATERIALS AND METHODS 
 
2.1  Study Design 
This is a cross sectional study conducted at STH involving retrospective review of 
records of MDR-TB patients seen and admitted at STH during 2001-2002. 
 
2.2 Study Setting 
The study was conducted at STH in Gauteng Province, South Africa. The STH is a 220-
bed hospital which functions as a centre for complicated tropical diseases, including 
malaria, trypanosomiasis, and yellow fever. It also plays an important role in the TB 
control program in the Gauteng Province as it was chosen as a referral hospital to 
handle complicated cases and also drug-resistant cases of tuberculosis. According to 
Gauteng guidelines, every MDR-TB patient should be referred to STH with a referral 
letter specifying the reason for referral, the name of the referring facility, the 
investigations used, the duration of treatment and HIV status if possible, and the result 
of sputum culture and sensitivity test.  
 
2.3 Study Population 
The study population for this research includes all patients seen and admitted at STH 
with a diagnosis of MDR-TB during 1 January 2001 to 31 December 2002. In this report, 
the following definition of MDR-TB was used to identify MDR-TB patient records for 
inclusion in the study: ―Drug sensitivity tests for both INH and Rifampicin show 
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resistance‖. In this study, NMDR-TB will refer to any TB patient whose sensitivity test 
does not demonstrate any resistance to both INH and Rifampicin, with or without 
resistance to other anti-TB drugs. This will included all PTB cases, extra-pulmonary 
cases and TB complications. 
 
2.4  Sampling  
Sampling strategy: Out of 3,706 TB cases seen and admitted at STH during the study 
period, 845 (23%) were MDR-TB patients. Of these 845 MDR-TB patients, 281 (33%) 
were selected by systematic sampling – starting from a random point, every third patient 
record listed in an admission register, was sampled and included in the study.  
 
Sample Size: Epi-info‘s Stat calc function (version 9.2) was used to calculate the 
sample size for this study. At the confidence level of 95% a sample of at least 205 
MDR-TB records was required. 281 MDR-TB records (which represented one third of all 
cases) were systematically selected; oversampling was done in order to be on the safe 
side, in case some records were incomplete.  
 
2.5 Data Collection  
Data were extracted from patient records which were kept in 3 separate storerooms and 
filed in ascending order following patient file numbers. A data collection sheet (Appendix 
1) was used to extract and capture data from hospital records. The following variables 
were extracted from the records and captured on the data collection sheet: 
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Socio-demographic variables:  
 Age, sex and race 
 Employment status: this was recorded as occupation. Those who had any 
defined occupation were taken as employed; those without any defined 
occupation were ―unemployed‖.  
 Housing structure: this was classified as a formal structure (flat, hotel, hostel, 
prison, private house; or an informal structure (shack and other non specific). 
 Place of residence: this was recorded in the files as ―address‖ – it was 
categorized in this study as town, suburb, township and informal settlement. 
 District of residence: Gauteng had five Districts at that time namely Sedibeng, 
West rand, city of Johannesburg, Ekurhuleni and Tshwane-Medsweding. 
 
Treatment history at referring facility: 
 Referring facility means: any health facility [e.g. clinic, hospital] which at any time 
in the provision of TB care refers a patient to the referral facility [STH]). 
 Investigations done to diagnose TB at referring facility: this refers to types of 
investigations that were done to make the diagnosis of TB. 
 Type of referring facility: clinics and community health centers were classified as 
PHC, others were hospitals. 
 Reason for the referral to STH: the reason that was mentioned in the referral 
note from the referring facility was captured (e.g. MRD-TB, E-PTB, TB 
complications etc). 
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 Past treatment history (duration of TB treatment (if any) before referral to STH: 
This refers to the time between treatment for normal TB till the time the sputum 
culture reveals MDR-TB. 
 
HIV status: this was categorized as ‗positive‘, ‗negative‘ or ‗unknown‘. HIV status was 
extracted from referral letters or from the laboratory report.  
 
Treatment history at STH was measured by the following:  
 Drug resistance patterns 
 Treatment received at STH 
 Duration of treatment (admission) at STH 
 Whether feedback letter to referral facility was issued on discharge 
 Types of TB complications treated while at STH. 
 
Drug resistance pattern: this refers to the classification of MDR-TB according to the 
WHO definition; Patients will be found to be resistant to one, two or more anti-TB drugs. 
The importance was to check resistance to the two major anti-TB drugs (H and R) 
 
Treatment received at STH: this refers to: 
 the clinical management provided during admission (see ‗definition of terms‘ 
above for clinical management options)  
 whether clinical management was in line with policy guidelines 
24 
 
 duration of treatment – which refers to the period between admission at STH till 
the patient died, was discharged, or absconded; and  
 whether feedback letters were given upon discharge (in accordance with 
guidelines). 
 
MDR-TB treatment outcomes were categorized as: 
 Successful outcome: cure, sputum conversion and treatment completion; or 
 Unsuccessful outcome: defaulted, died, failed treatment (treatment failure), loss 
during follow up, relapsed and transferred out. 
 
Cure was defined as a patient who is smear-negative at one month prior to the 
completion of treatment and also on at least one previous occasion. Sputum conversion 
was defined as the fact that positive smear detected by microscopy has become 
negative under the effect of an appropriate treatment during a period of normally 9 
months. Treatment completed is when the patient has completed treatment but without 
proof of cure (i.e. smear results are not available on at least two occasions prior to the 
completion of treatment).  
 
Variable for unsuccessful outcome were defined as follows: default referred to a case 
where treatment was interrupted for a period of time mostly due to patient related 
reasons; died referred to a patient who died for any reason during MDR-TB treatment; 
failed treatment (treatment failure) was a patient who remained positive or was again 
smear positive five months after starting treatment; loss during follow up was defined as 
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a patient who did not return for treatment during the period after starting his TB/MDR-TB 
treatment. Relapsed was a sputum smear positive pulmonary TB patient who received 
treatment and was declared cured (sputum smear negative) at the end of the treatment 
period and has now developed sputum smear positive pulmonary TB again; and 
transferred out is when a patient already registered for treatment in one district and who 
had been transferred to another to continue treatment (treatment outcome not known). 
 
Data was extracted from the records by two trained field workers, the principal 
investigator and one retired professional nurse. The principal investigator also verified 
the data by randomly rechecking 100 cases from the patient register. Patient details 
were linked to the data collection sheet with the hospital number only, and no patient 
names were entered onto the data collection sheet. 
 
2.6 Data management and analysis 
Data were captured electronically onto a Microsoft Excel spreadsheet, and this was 
imported into Epi-Info Version 9.2 for quantitative analysis. Descriptive statistics 
(minimum and maximum, mean and standard deviation, and median and inter-quartile 
range) were used to describe numeric data (age, and duration of treatment). 
Proportions were used to summarize categorical data and determine frequency 
distributions of the variables of interest.  
 
The one sample t-test (Student‘s t-test) statistic was used to perform test of association 
between numerical data (to compare mean age) and MDR-TB treatment outcome; and 
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chi squared test was used to assess association between socio-demographic, treatment 
history characteristics with treatment outcome. These tests of association were done 
using Epi-info and a probability value (p-value) of less than 0.05 was considered to be 
statistically significant, and confidence limits were set at 95%. 
 
2.7 Ethical Considerations 
The permission of the Gauteng Health Department was obtained to conduct the study in 
the province. Ethics clearance (number M030816 – see attached) was obtained from 
the Wits Ethics Committee. Permission was granted by the Chief Executive Officer 
(CEO) of STH to access hospital records, including information from referring facilities. 
Information was treated confidentially. No patient‘s names were collected and records 
were identifiable through a unique study record number only. While there was no direct 
benefit to individual patients, it is hoped that the result of this study will influence policy 
making and health service delivery at STH and the referring facilities, and thus may in 
the future indirectly benefit patients at STH. 
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CHAPTER 3: RESULTS 
During January 2001 to December 2002, 3,706 TB cases were seen at STH (845 MDR 
and 2,861 non-MDRTB patients). Of the 845 MDR-TB bases, 281 were reviewed in this 
study. The results are presented in this chapter, according to the objectives of the study. 
 
3.1 Patient’s socio-demographic profile  
The mean age of MDR-TB patients was 37 years (SD 11.4), the median 36 (IQR 30-44); 
the means age by sex were 38.3 for male, 34.3 for female. Furthermore, the majority of 
MDR-TB was males (62%), black (94%), unemployed (72%), living in formal housing 
structures (91%) and residing in township (62%). Except the mean age, these 
descriptive data are summarized in Table 3.1.1.  
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Table 3.1.1: Socio-demographic profile of MDR-TB patients at STH: 2001-2002. 
Characteristics N % 95% CI 
Sex Male 175 62 56.5-68.1 
 Female 106 38 31.9-43.5 
Total 281 100  
Race Black 264 94 90.5-96.4 
Colored 11 4 2.0-6.9 
 Indian 2 1 0.1-2.5 
White 4 1 0.4-3.6 
Total 281 100  
Employment  
status  
Employed 79 28 23.2-34.0 
Unemployed 202 72 66.0-76.8 
Total 281 100  
Place of  
Residence  
Township 173 62 55.4-67.1 
Town and suburb 107 38 32.6-44.2 
Informal settlement  1 0 0.0-2.0 
Total 281 100  
Housing  Formal housing     
type 
 
 
 
 
Private house 202 71.9 67.2-81.7  
Flat 25 8.9 5.8-12.8 
Hotel 14 5.0 ?? 
Hostel 13 4.6 2.7-8.2 
Prison 3 1.1 1.2-5.5 
Informal housing     
Shack 10 3.6 2.5-7.8 
Not specified    
Not indicated on record 14 5.0 1.9-9.5 
Total 281 100  
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3.2: Patient treatment history at the referring facilities  
Patients treatment history at the referring facilities included the duration of treatment at 
facilities level, the investigations used to diagnose MDR-TB, the referral characteristics. 
Sputum tests alone or in combination with x-ray were most commonly used to 
investigate and diagnose MDR-TB (98%) at referring facilities (Table 3.2.1). 
Table 3.2.1: Investigations used to diagnose MDR-TB at referring facilities. 
Type of investigation used MDR-TB patients 
 N % 95% CI 
Sputum test with routine X-ray together 255 91 86.8-93.9 
Sputum test alone (sputum culture and sensitivity)  21 7 3.8-13.2 
Only X-ray 4 2 0.4-3.6 
No sputum and no X-ray done 1 0 0.0-2.0 
Total 281 100  
 
The mean duration of TB treatment at referring facilities (recorded as past treatment 
history) was 32 weeks (SD: 38.11) and a median of 24 weeks (IQR 12-39). The majority 
of patients arrived at STH with a referral note (98%); most referred from clinics/CHC 
(81%) and the major reason for referral was confirmed MDR-TB. These referral 
characteristics are summarized on table 3.2.2. 
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Table 3.2.2: Referral characteristics of MDR-TB patients: 2001-2002 
Referral characteristics MDR-TB patients 
Variable  N % 95% CI 
Referral letter Had a referral letter 276 98 95.9-99.4 
 No referral letter 5 2 0.4-5.6 
Total 281 100  
Reason for 
referral 
TB contact 1 0 0.0-2.0 
PTB 21 8 4.7-11.2 
Extra pulmonary TB 1 0 0.0-2.0 
TB complications 2 1 0.1-2.5 
Suspected MDR-TB 7 2 1.0-5.0 
Confirmed MDR-TB 249 89 84.4-92.1 
Total 281 100  
Referring  
Facility 
Self referral 3 1 0.2-3.1 
Clinic/CHC 228 81 72.3-89.8 
Private sector 4 2 0.4-5.6 
Public hospital 10 4 1.7-6.4 
SANTA hospital 20 7 4.4-10.7 
Tertiary hospital 15 5 3.0-8.6 
Other/NGOs 1 0 0.0-2.0 
Total 281 100  
 
3.3 HIV status of MDR-TB patients 
Over a third of MDR-TB patients (39%) in this study were HIV positive and 124 (44%) 
did not know their HIV status as depicted in table 3.3.1. The proportion of HIV positive 
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cases was statistically significantly higher (more than double) than HIV negative cases 
(17%). 
Table 3.3.1: HIV status of MDR-TB patients admitted to STH: 2001-2002 
HIV status of MDR-TB patients N % 95% CI 
HIV Positive 110 39.2 33.6-45.3 
HIV Negative 47 16.7 12.5-21.5 
HIV Unknown 124 44.1 38.1-50.0 
Total 281 100  
 
 
3.4 MDR-TB Patients treatment characteristics while admitted at STH 
The treatment characteristics included the following: duration of stay at STH, drug 
resistance profile, treatment received at STH, and feedback note. The mean duration of 
stay at STH was 64 weeks for all patients in general (SD 51) with a median of 56 weeks 
(IQR 21-89, but in HIV positive cases the mean duration of stay was 58 weeks (SD  51) 
with a median of 48 weeks (IQR 13-88).  
The other treatment characteristics showed that all patients (100%) were resistant to at 
least both H and R, of which 77% (N= 217) received standardized treatment, 22% (N= 
60) received individualized treatment, 1% (N=3) received an adjunction of surgical 
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treatment and 90% received feedback on discharge. A summary of these results is 
displayed in Table 3.4.1 
 
Table 3.4.1: Treatment characteristics of MDR-TB patients at STH: 2001-2002. 
 
Characteristics  N % 95% CI 
Drug resistance 
profile 
INH+ RIF only 120 43 36.7-48.6 
INH + RIF + 1 other drug 83 30 24.2-35.1 
INH+RIF+STREPT+EMB 77 27 22.2-32.9 
INH+RIF+STREPT+EMB 
+more other drugs 
1 0 0.0-2.0 
Total 281 100  
Treatment 
received at  
STH  
Individualized treatment 60 22 16.6-26.5 
Standard treatment 217 77 72.0-82.1 
Adjunction of surgical 
treatment 
3 1 0.2-3.1 
TB treatment Regimen 1 1 0 0.0-2.0 
Total 281 100  
Feedback note Feedback note 253 90.0 86.0- 93.3 
No feedback note  27 9.6 6.4-15.6 
Missing 1 0.4  
Total 281 100  
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3.5 MDR-TB treatment outcomes at STH  
The majority of patients had a successful treatment outcome (75%); and amongst those 
with unsuccessful outcomes, a significant number had died (17%). It was noticed that 
some outcomes were not recorded in patients files e.g. relapse, remained on treatment, 
and referred to surgery. This descriptive data is summarized in table 3.5.1. 
 
Table 3.5.1 Treatment outcomes for MDR-TB patients at STH: 2001-2002. 
 
 
 
 
 
 
 
 
 
 
 
Treatment outcomes N % 95% C.I 
Successful outcomes    
Conversion at 9 months 174 61.9 56.5-68.1 
Cured 36 12.8 9.1-17.2 
Subtotal of successful outcomes 210 74.7  
Unsuccessful outcomes    
Defaulted  15 5.3 2.3-10.5 
Death 46 16.4 12.2-21.2 
Transfer out  1 0.4 0.0-2.0 
Treatment failure 8 2.8 1.2-5.5 
Subtotal of unsuccessful outcomes  70 24.9  
Missing 1 0.4  
Total  281 100  
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The study explored the association between socio-demographic characteristics (age, 
sex, race, employment status, area of residence, district of residence, housing 
structures) and treatment outcomes as well as between clinical characteristics (duration 
of treatment at facility level, MDR-TB resistance profile, treatment received at STH, 
feedback note received and duration of treatment at STH and HIV status) and treatment 
outcomes at STH. These associations were calculated using a Chi-squared test of 
association. The results are summarized in the table below. Only associations which are 
statistically significant (p< 0.05) are represented in the tables.  
 
The factors that are statistically significantly associated with MDR-TB treatment 
outcomes at STH were feedback given to the referring facility, HIV Status and housing 
type, as shown in table 3.5.2.1. Those patients for whom formal feedback was given by 
STH to their referring facility were more likely to achieve better outcomes (sputum 
conversion at 9 months and cure) than those who did not have referral feedback. Death 
as a poor outcome was more likely to occur in patients for whom no feedback was 
provided to referring facilities. The findings also show that HIV negative patients were 
more likely to achieve better outcomes; and patients living in formal houses (hostel, 
private house, flats and hotel) had better outcomes than those living in shack and 
prison.   
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Table 3.5.2.1: Association between MDR-TB treatment outcomes and socio-
demographic and treatment characteristics of patients at STH: 2001-2002  
 
 
                        MDR-TB Treatment outcomes 
[No. (%)] 
p-value 
Explanatory 
variables 
Sputum 
conversion 
at 9 months 
Cure 
 
 
Death 
 
 
Default 
 
 
Transfer 
out 
 
Treatment 
failure 
 
 
Feedback given to referring facilities 0.0000 
Yes 172 (68,3) 34 (13.5) 23 (9.1) 14 (5.6) 1 (0.4) 8 (3.2) 
No 2 (7.4) 1 (3.7) 23 (85.2) 1(3.7) 0 (0.0) 0 (0.0) 
HIV Status 0.0000 
Positive 60 (54.5) 8 (7.3) 35 (31.8) 4 (3.6) 0 (0.0) 3 (2.7) 
Negative 33 (70.2) 7 (14.9) 4 (8.5) 0 (0.00 0 (0.0) 3 (6.4) 
House type 0.015 
 
 
 
 
Hostel 10 (76.9) 0 (0.0) 3 (23.1) 0 (0.0) 0 (0.0) 0 (0.0) 
Private house 122 (60.4) 29 (14.4) 37 (18.3) 6 (3.0) 1 (0.4) 7 (3.5) 
Flat 19 (76.0) 3 (12.0) 2 (8.0) 1 (4.0) 0 (0.0) 0 (0.0) 
Hotel 10 (71.4) 0 (0.0) 1 (7.1) 3 (21.4) 0 (0.0) 0 (0.00 
Shack 5 (50.0) 0 (0.0) 1 (10.0) 4 (40.0) 0 (0.0) 0 (0.0) 
Prison 1 (50.0) 1 (50.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
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 The study further found that amongst the 46 patients who died, over three-quarters of 
them (76.1%) were HIV positive, 15.2% had an unknown HIV status, and 8.7% were 
HIV negative. These findings are summarized in the Figure 3.5.1 below.  
 
 
Figure 3.5.1 Distribution of HIV status among the deceased (n=46) 
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CHAPTER 4:  DISCUSSION AND LIMITATIONS 
4.1. Discussion 
This study describes the socio-demographic characteristics, diagnostic and treatment 
history at referring facility level, HIV status, treatment history at STH and treatment 
outcomes at STH of MDR-TB patients, and factors associated with treatment outcomes. 
The findings of the study reveal that there are issues around areas which have serious 
influence on MDR-TB management in Gauteng. The issues pertain to socio-
demographic characteristics of the patients, non compliance to MDR-TB management 
policies, HIV and TB co-infection, and MDR-TB treatment outcomes. These issues are 
discussed below. 
 
4.1.1 Socio-demographic profile 
This study has shown that the mean age for MDR-TB patients was relatively young at 
37 years. The result is quite comparable with the study in Iran where the mean age was 
found to be 44.38 +/- 19.05 years (Masjedi at al., 2008). Likewise, other studies in 
Taipei, Taiwan and at Santa Cruz in Bolivia, found quite comparable mean ages (43.3 
years and 33.9 years respectively) to the mean age found in this study (Chiang et 
al.,2006; Ollé-Goiget al., 2005). In South Africa a study at Ngwelezane hospital in the 
Northern Kwazulu Natal found that the mean age of TB patients was 29.6 years, with 
the highest notification age ranging between 25 and 34 years old, still in the comparable 
limit if one considers that naturally a person would suffer from TB first and then later 
develop MDR-TB as a complication if TB is not well managed (Lin et al., 2004). This 
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age group represents the working force in South Africa, thus the negative socio-
economic impact of TB and MDR-TB in our society. 
 
It was also found that the majority of MDR-TB patients were male. This finding is in 
accordance with literature that reveals that there are generally more males than females 
suffering from TB and MDR-TB worldwide ( Masjedi et al., 2008; Dhingra et al., 2008; 
Chiang et al., 2006; Ollé-Goig et al., 2005; Lin et al., 2004). In addition more MDR-TB 
patients were black, probably because the users of STH are mainly black people since 
traditionally public hospitals cater largely for the black catchment population 
representing the majority population in SA, and therefore this result is not surprising. 
However, generally social inequalities related to race are a real issue in South Africa 
and the rest of Africa and this has great influence on TB/MDR-TB acquisition especially 
in the context of poor living conditions associated with poor nutrition and overcrowding 
(Nhlema et al., 2003). In South Africa the majority of black people live in poor conditions 
where they are vulnerable to contract TB and MDR-TB. . 
 
The study further revealed that the majority of patients were unemployed, living in 
formal types of houses, and residing in townships.  Employment status, types of 
housing and the area of residence are commonly used to determine the socio-economic 
status of individuals in the community as poverty is strongly associated with TB and 
MDR-TB. (Nhlema et al., 2003)  
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4.1.2 Compliance with policies (Referral and Diagnosis of MDR-TB) 
In this section focus will be placed on compliance with organizational structural policy on 
the one hand and MDR-TB management policy guidelines on the other hand. 
Organizational structure means that in principle, STH was designated as a specialized 
centre for the treatment of MDR-TB patients in Gauteng, but in practice, this centre was 
functioning like a normal TB hospital with an extension ward for MDR-TB patients. For 
instance this study reported that in the period between 2001 and 2002, from a total of 
3706 TB patients seen at STH only 845 (23%) were MDR-TB cases. 
 
The mean duration of MDR-TB treatment or stay at the referral facility level (STH) was 
64 weeks which is quite long. The study also showed a long mean duration of treatment 
at referral facility level of about 31 weeks, before referral to STH.  According to national 
policy the duration of normal TB treatment is six months for new cases and 8 months for 
re-treatment cases divided into an initial and continuation phases (NDoH, 2004). Newly 
diagnosed MDR-TB patients at a referring facility should be transferred to STH 
immediately after a diagnosis of MDR-TB has been made (NDoH, 2007) to start MDR-
TB treatment since the delay in starting MDR-TB treatment has a serious effect on the 
treatment outcome (Schaaf et al; 2003). But this study showed that patients waited 31 
weeks on average to be transferred to STH. Such a situation could be related to delays 
in obtaining laboratory results and/or the fact of commencement of a TB treatment on 
the basis of an X-ray or clinical features. 
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A further finding was that 98% of patients were sent to STH with a referral note, a good 
indication of adherence to national policy guidelines on referral. Moreover generally 
more patients (80%) were referred to STH from clinics than other facilities. Further 
investigation needs to be initiated to check with other referring facilities whether they do 
adhere completely to the policy that stipulates that STH is the provincial specialized 
centre for the treatment of MDR-TB patients or whether these facilities have fewer 
cases of MDR-TB or are perhaps treating them themselves. Another explanation could 
be that staff in clinics and CHCs is more exposed to training than those from other 
facilities. Also, hospitals and most especially at tertiary level, might be treating MDR-TB 
themselves which is against protocol. The study further discovered a few cases of self 
referral to STH (1%) which again is against the protocol. 
 
In assessing a reason for referral, it was found that the majority of patients (89%) 
referred to STH were confirmed MDR-TB. There is no indication in the records as to 
whether the referring facilities or STH did the sputum culture tests. The policy guideline 
recommends that the laboratory results should come from the referring facilities. Any 
delay in referring patients will cause delays in commencing treatment. 
 
In terms of the diagnosis of MDR-TB, this study demonstrated that 91% of patients who 
had laboratory tests to confirm MDR-TB, had also an X-ray done, and that laboratory 
tests alone were only done in 7% of cases. A laboratory sputum test is a clear indicator 
of adherence to national policy and a measure of the quality of a diagnosis. The policy 
states clearly that a laboratory test is the first choice diagnostic method in the diagnosis 
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of TB and a tool to monitor treatment progress after five months. A sputum for culture 
and susceptibility testing is only required if the patient still remains positive at the end of 
the intensive phase. The policy also defines clear guidelines of the use of X-rays in the 
diagnosis of TB and MDR-TB. These are: suspicion of complications (Pneumothorax, 
pleural effusion); frequent or severe Hemoptysis; diagnosis of other lung diseases; 
clinical TB after a negative smear; and treatment progress (NDoH, 2004). No check was 
made as to whether or not these two investigations were done simultaneously. Or given 
an indication as to whether the X-rays were taken according to protocol or not. On the 
other hand the guidelines also state that too much reliance on chest X-ray in the 
diagnosis of TB results in unnecessary treatment, because chest X-ray is not a reliable 
predictor of active TB (DoH), 2004). Furthermore, the study showed that 1% MDR-TB (4 
cases) had no laboratory tests done; 1 case of MDR-TB had not been investigated at 
all. The above gives some indication of non- adherence to policy. Further study needs 
to be conducted to assess the reason for this and too much use of chest X-ray in this 
facility. 
 
The treatment received at STH was relatively in accordance with the policy in exception 
of two elements. Firstly the study showed a serious concern about the one patient who 
being diagnosed MDR-TB as others (100%) but received TB regimen one treatment! 
Secondly, the study could not determine the MDR-TB treatment received by the three 
MDR-TB patients who were on adjunction of surgical treatment. There is a policy issue 
there as well.  
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In summary the study has found that referral facilities are not following the correct 
procedure to diagnose MDR-TB as stipulated in the National TB guidelines. The 
consequence of this malpractice has led to a situation where some cases who have 
ended up at STH as MDR-TB are actually not infected (11%), but many of these 
patients are actually TB cases or have TB complications.  
 
4.1.3 Treatment of MDR-TB at STH  
The duration of treatment/stay at STH is an important factor to consider. On average, 
MDR-TB patients stayed 63.59 weeks (about 16 months). Considering the time these 
patients have spent at a referring facility it can be concluded that up to a total of 94.58 
weeks (about 24 months) for MDR-TB is spent in treatment, which is too long. These 
findings are quite similar to a study by Edgington et al. where it was found that the mean 
duration of patients stay at STH was 28 months (Edginton & Joffe, 2004). As stated 
previously, national policy has specified that the total duration of MDR-TB treatment 
should be 19 months (76 weeks). The mean duration of stay found in this study was 
also comparable to the study by Ward et al in Vietnam where the mean duration of 
treatment for MDR-TB was 23.0 (SD+/-11.4) months (Ward et al., 2005). 
 
Length of stay or duration of treatment at STH is showing how long the patients are 
taken into charge by the referral facility. This is a very important socio economic 
parameter. The attempt to assess predictors of ―duration of stay at STH‖ showed no 
significant association but it is not clear at this moment how this influence can be 
evaluated.  
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This policy states clearly that the diagnosis to confirm a MDR-TB case should be made 
at facility level before the patient is referred to STH. In that case the laboratory test 
should show a sputum resistant to at least the two powerful anti TB drugs: H and R 
(NDoH, 2007).  
 
The study has revealed that confirmed MDR-TB cases at Sizwe were classified into four 
groups: those resistant to the two major TB drugs, H and R (43%), those who were 
resistant to three TB drugs including H and R(30%) also called  ―poly-resistant-TB‖ by 
STH staff, those  who are resistant to all 4 first line TB drugs (SHRE) (27%)  locally 
called  ― high grade resistant-TB‖ by the staff at STH  and finally one case resistance to 
6 drugs after 9 months treatment and was , classified as ―treatment failure‖ by the local 
staff. Recently, another group was added to the MDR-TB cases. These are the XDR-TB 
(Extremely or Extensively Drug Resistant Tuberculosis) defined by WHO  as resistance 
to at least Rifampicin and Isoniazid (MDR-TB), in addition to any Fluoroquinolone, and 
at least one of the three following injectable drugs Capreomycin, kanamycin, and 
Amikacin over and above resistance to INH and RIF (DoH, 2004). A precise 
classification of cases is therefore important and will consequently determine 
appropriate treatment .This study demonstrated that the majority of MDR-TB received 
standardized treatment (77%) while a few others received individualized treatment 
(21%), only 1% received surgical treatment and one case of treatment misclassification 
who received TB treatment regimen 1. This shows that at STH, the protocol for the 
treatment of MDR-TB is commendable. At STH poly-resistant TB patients, all high grade 
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resistant-TB and all treatment failure cases are given individual treatment after drug 
susceptibility test results are obtained which is good practice. 
 
4.1.4 Treatment Outcomes of MDR-TB 
Generally in literature, MDR-TB treatment outcomes are measured in terms of success 
or non success (unsuccessful). Successful outcomes will be cure, treatment completion, 
good conversion rate while unsuccessful outcomes which are most common in MDR-TB 
treatment are death, default, failure and absconding (Laserson et al., 2005). Non 
compliance to policy guidelines by the provider as well as by the patient will lead to poor 
or unsuccessful outcomes. 
  
The conversion rate at 9 months in this study was low 62% which is low. These findings 
in the study by Holtz  et al (2006) in Latvia revealed that among 167 patients who were 
sputum culture-positive at initiation of second-line therapy, 129 (77%) converted in a 
median time of 60 days (range, 4 to 462 days) and 38 (23%) did not convert (Holtz et 
al., 2006). Other studies have revealed cases of poor MDR-TB treatment outcomes in 
different setting including the Western Cape, Estonia, Germany, Italy, Russia federal 
and Srilanka (Shean et al., 2008; Migliori et al., 2008 ;Ollé-Goig,  2005 ; Senaratne, 
2004;Mishkinis et al., 2000.)  
 
Good outcomes have been reported by Masjedi et al in their study on the outcome of 
treatment of MDR-TB patients with standardised regimens in Iran during 2002-2006 
where 67.5% had a successful outcome (Masjedi et al., 2008). Another situation of 
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successful outcomes is reported in the study on monitoring tuberculosis treatment 
outcome: analysis of national surveillance data from a clinical perspective  study  by 
Ditah et al where the success rate was 76.8% using WHO/IUATLD criteria or 87.5% 
success rate when applying the new criteria (Ditah et al., 2008). Good outcomes in 
terms of cure or treatment completion were achieved with the MDR-TB treatment as 
was the case all over the world: (Chiang et al., 2006; Leimane et al., 2005; Chan et al., 
2004;Toungoussova et al., 2004). 
 
This study has shown the importance of giving feedback by the referral facility to the 
referring facilities about their patients. The feedback would include the final diagnosis, 
the proposed treatment and the follow up schedule as well as some instructions on 
DOT, and non interruption of the treatment. According to this study, giving feedback will 
improve outcomes and not giving feedback will lead to poor outcome especially death. 
 
 In general HIV was demonstrated to have an association with MDR-TB treatment 
outcomes in this study; but the limitation is that HIV data were not available on all 
patients. HIV negative patients were more likely to achieve better outcomes. It was 
difficult to comment about the association between HIV positivity with either good or 
poor outcomes. But HIV positive was more likely to be associated with death than HIV 
negative. In contrast, the study by Dedha revealed no association between death and 
HIV positive or negative status(Dheda et al., 2010). 
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Finally, this study revealed a significant relationship between types of house and 
treatment outcomes, and living in formal houses (hostel, private house, flats and hotel) 
has influence in achieving better outcomes than living in shack and prison.   
 
The literature previously confirmed that experience with MDR-TB treatment outcomes 
varies in different settings. For example, a descriptive study conducted in 1996 in Santa 
Cruz, Bolivia revealed that a successful outcome was achieved in 28% of patients, while 
48% defaulted, and 13% died and 10% were still under treatment in 1996 (Olle-Goig 
and Sandy., 2005). Another study by Tupaisi et al in the Phillipines showed a cure rate 
of 73.4%, a failure rate of 3.8% and a likely failure rate of 6.3%; while death occurred in 
3.8% and defaulting was observed in 11.4 % (Tupaisi et al., 2003). Latvia has one of the 
highest rates of multidrug-resistant tuberculosis (MDR-TB). In a study conducted there 
to assess treatment outcomes for the first full cohort of MDR-TB patients treated under 
Latvia 's DOTS-Plus strategy following WHO guidelines, it was demonstrated that of the 
204 patients assessed, 55 (27%) had been newly diagnosed with MDR-TB, and 149 
(73%) had earlier been treated with first-line or second-line drugs for this disease. 
Assessment of treatment outcomes showed that 135 (66%) patients were cured or had 
completed therapy, 14 (7%) had died, 26 (13%) had defaulted, and 29 (14%) had 
treatment failure. Of the 178 adherent patients, 135 (76%) achieved a cure or treatment 
completion which is an example of a good outcome (Leimane et al., 2005). In this study, 
death rate is also high (16%) which is equivalent to 16000 deaths per 100 000 
population. 
47 
 
In this study receiving feedback letters, HIV status and type of housing seem be most 
associated with treatment outcomes. According to published literature TB treatment 
outcomes are influenced directly or indirectly by a number of factors, including socio-
demographic characteristics (age, sex, education level and economic status), treatment 
delay, inappropriate prior TB treatment with poor adherence (inefficient DOTS strategy 
and referral system), poor prescription and provision of drugs, staff bad attitude, HIV 
sero-positive status, previous TB treatment for more than 4 weeks, smoking (for 
Isoniazid resistance), the presence of cavitations on the chest radiograph, and 
imprisonment (Ekaterina et al., 2006). Other literature stresses predictors of good 
outcomes as weight gain at six months, culture conversion, radiologic improvement 
during treatment, resistance to less than or up to the three anti-tubercular drugs, use of 
less than or up to three second line drugs in treatment and no change of regimen during 
treatment (Dhingra et al., 2008).  
 
HIV infection is one of the most common determinants of poor outcomes in TB/MDR-TB 
with negative influence on the incidence alongside with previous TB treatment, 
resistance to Ofloxacin and the positive start of treatment (Kliiman, K and Altraja, A., 
2009). In 2008 WHO reported an estimate of 9.4 million incidence cases of TB, 11.1 
million prevalence cases of TB, 1.3 million deaths among HIV negative TB patients and 
0.52 million deaths among HIV positive TB patients (WHO, 2008). In 2008 WHO 
reported an estimate of 9.4 million incidence cases of TB, 11.1 million prevalence cases 
of TB, 1.3 million deaths among HIV negative TB patients and 0.52 million deaths 
among HIV positive TB patients (WHO, 2008).  
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4.1.5 TB/HIV co-infection 
This study revealed that the prevalence of HIV amongst MDR-TB patients was 39%. It 
also found that there is more HIV infection in male patients than in females with MDR-
TB. One reason could be that there were more males than females under review. This 
is a challenge in S.A where it has been found that more females than males are HIV 
positive; but in the context of TB/MDR-TB, there are more male than female HIV 
positive cases mostly because the male gender is more affected by this condition. 
Literature indicates that in general, HIV infection is significantly associated with TB/ 
MDR-TB and TB is a leading cause of death among people who are HIV positive since 
HIV is the single most important factor determining the increased incidence of TB in 
Africa. (Espinal et al., 2001; Fujita, 1998). 
 
In SA, HIV testing is generally not compulsory. VCT is being used for individuals to find 
out their HIV status. In the context of the HIV-TB co-infection it would be recommended 
that VCT be offered to all TB/MDR-TB patients. But a policy of compulsory HIV testing 
(even if this was legal) of TB patients in general would be counterproductive. This type 
of policy may result in patients deterred from seeking care, decreased case-finding in 
at-risk groups and reduced credibility of health services.  A notable achievement is the 
fact that all Gauteng TB hospitals and most community health clinics are VCT and ARV 
sites.  
 
Another issue was to evaluate association of HIV status with duration of stay in hospital. 
This study found that in the HIV positive population the average duration of 
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stay/treatment at STH was shorter; at 58 weeks (14 months) for MDR-TB patientough 
there was no significant difference. Endeavoring to establish whether HIV was a 
contributing factor to death, the study revealed that amongst the 46 patients who died, 
over three-quarters of them (76.1%) were HIV positive, above the rate found in a study 
by Quy et al where death during treatment occurred in 15 of 50 HIV-infected patients 
(30%) (Quy et al, 2006). HIV infection may lead to mal-absorption of anti-TB drugs and 
acquired Rifampicin resistance. HIV-infected patients with MDR-TB have a high 
mortality take, thus the necessity of both anti-retroviral and anti-myco bacterial 
treatment.  Surveillance data suggests that in several countries HIV infection and MDR-
TB may converge. Furthermore institutional outbreaks, overwhelmed public health 
program, and complex clinical management issues may contribute to the convergence 
of the MDR-TB and HIV infection epidemics. Thus infection control, rapid case 
detection, effective treatment, and an expanded program capacity are needed urgently 
(Wells et al., 2007). 
 
Finally drug resistance, specifically multidrug resistance and extensive drug resistance, 
is a serious threat to public health in all countries. For instance in the Russian 
Federation the highest rates of multidrug resistance are presently accompanied by a 
rapid increase in HIV infection. The collaborative effort of different organizations, 
professionals and communities is needed to address the development and spread of 
multidrug resistance and extensive drug resistance, which combined with the epidemic 
of HIV infection is one of the barriers to dealing effectively with TB. This effort should be 
directed towards facilitating the diagnosis and treatment of TB patients, in particular by 
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improving access to drug susceptibility testing and strengthening treatment delivery by 
rigorous adherence to DOTS as outlined by the Stop TB Partnership (Blöndal  et al., 
2007). Strong TB control will be facilitated by scaling-up WHO-recommended TB/HIV 
collaborative activities and by improving coordination between HIV and TB control 
programs, in particular, to ensure control of drug-resistant TB. The study concluded that 
integrating the care and treatment of TB and HIV in high prevalence areas is a 
necessary strategy as confirmed by the recently completed Starting Antiretroviral 
Therapy at Three Point in Tuberculosis Therapy (SAPIT) trial which showed that 
integrated treatment of HIV and TB in an urban African setting improves outcomes, 
reduces mortality, and is more effective than sequential treatment (IDSA News,  2010). 
 
4.2 Limitations 
 The research team was unaware of how representative the cases at STH were of 
the MDR-TB population. From the distribution of cases, it seems that other cases 
were missing. 
 The study was a record review from a facility and relies on the accuracy of record 
keeping. Other cases of MDR-TB in the region may have been referred to the 
facility and not arrived, or they may not have been referred to the facility at all. 
Some patients may have died prior to arriving at the facility. 
 A case control study would have had to be used to determine the association 
between MDR-TB and each of the factors being studies in this project. 
 Incomplete records made it difficult to obtain the full information needed. 
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 The study was not able to assess the relationship between MDR-TB and the 
previous treatment. 
 The study did not go as far as using mutli-variate regression analysis to measure 
the relationship between each sub category of independent variables with each 
outcome. 
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CHAPTER 5: CONCLUSION AND RECOMMENDATIONS 
 
5.1 Conclusion 
The study demonstrated that treatment given at STH was not always standardized. 
Individual treatment was given in some cases of high grade MDR-TB, poly-resistance 
TB and treatment failure. It has also shown that socio-demographic characteristics of 
patients described favor TB development and were clearly evident of the majority of the 
community dealt with (black majority, unemployed, living in township and in the informal 
settlement.  
 
In general the treatment characteristics were equivocal (commendable referral system 
with unclear methods used to confirm MDR-TB and unjustified long duration of 
treatment prior to referral). Past treatment history was explored and revealed that there 
was no compliance to the organizational policy given the fact that STH was used for 
treatment of all type of TB infections (MDR-TB, XDR-TB, PTB and extra-PTB). Although 
in general the majority of patients had successful treatment outcomes, the policy 
guidelines of the management of MDR-TB were not implemented fully and that led to 
some cases of mismanagement resulting in poor outcomes. Finally predictors of poor 
outcomes in terms of death and default were not giving feedback, HIV status and 
housing types.  
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5.2 Recommendations 
The Provincial TB control policy stipulates that all Gauteng MDR-TB patients should be 
referred to STH. But there was no written policy about the role to be played by STH in 
the management of TB and MDR-TB patients. The following are direct 
recommendations from this study: 
 There is an urgent need to define clearly the role of STH as a MDR-TB hospital 
only with clear admission and discharge criteria taking into account staff 
workload (including the burden of XDR-TB), and the existence of a number of TB 
hospitals around Gauteng. 
 Private sector should also conform to the policy guidelines. Currently it is not 
known where this sector sends its MDR-TB cases.   
 Staff in the referring facilities needs to be trained to understand that TB/MDR-TB 
is diagnosed by a laboratory test first, except those cases where an X-ray or 
other investigations are indicated. 
 There is a need to conduct further studies to check what causes delays in 
laboratory investigations. It is time to explore the possibility of developing rapid 
testing for MDR-TB. 
 It is important to check what the hospital policy is regarding HIV testing, to know 
whether it is a routine test for those who give consent or not. In the light of 
antiretroviral treatment (ART), it is particularly important that every person with 
MDR-TB is tested for HIV. 
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 The reporting or notification system should be improved to allow for accurate 
calculations, and also for conducting other statistical analysis in terms of the 
relationship between various contributing factors. 
  It is important to tackle predictors of poor MDR-TB treatment outcomes in future: 
stronger study designs like case-control studies may be needed to do this. 
 There is a need to trace where other racial groups have been treated for MDR-
TB by conducting further studies. 
 It is important to tackle predictors of poor outcomes in future: well defining the 
role of STH as related to the treatment of MDR-TB patients, improve feedback 
mechanisms, and improve VCT policies for MDR-TB patients. 
 It is also recommended that patients should be hospitalized for at least the first 
few months until they have produced three consecutive monthly cultures of-
negative sputa. 
 
Generally, early diagnosis and treatment of TB cases, a well-implemented DOT system, 
well-planned follow up of patients (laboratory and X-ray tests), well-trained and 
dedicated health care professionals; and an informed and adherent population are key 
elements for preventing the occurrence of MDR-TB and improving TB control. Given the 
impacts of HIV, integration of TB and HIV services should be encouraged, especially at 
the outlying areas. This is important to effectively treat those infected with both 
diseases, to prolong their survival and to maximize limited human resources. Globally, 
renewed attention to TB/HIV collaborative activities is recommended, combined with 
committed political will (Laserson et al., 2007; Quy et al., 2006).  
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APPENDICES 
Appendix 1: Data Collection Sheet 
 
FILE NUMBER __________                                              Entry no:_________________ 
 
1. SOCIO-DEMOGRAPHIC CHARACTERISTICS: 
1.1 YEAR of admission: 
1.2 AGE/DOB:                                                                      
1.3 SEX:                F / M                      
1.4 RACE:             Black               Coloured                    Indian               White                              
1.5 PLACE OF RESIDENCE (address):      Informal settlement,  
                                                                     Township,  
                                                                      Suburb  
                                                                      and Town                                                       
     DISTRICT OF RESIDENCE (part of address) : Johannesburg 
                                                                              West Rand 
                                                         Ekurhuleni 
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                                                         Sedibeng 
                                                         Tshwane 
                                                            Metsweding 
1.7 EMPLOYED:                  Yes / No     
1.8 TYPE OF HOUSING (or housing structure if available)                 
                                                            Informal Housing structure: (shack and other 
                                                            non specific)( 
                                                            Formal housing structure: (flat, hotel, hostel,  
                                                            prison, private house) 
                                                            
2. TREATMENT HISTORY AT REFERRING FACILITY 
2.1 TYPE OF REFERRING FACILITY:             Self                                                    
                                                                           Clinic 
                                                                           CHC                                     
                                                                            Private Doctor 
                                                                            Hospital (public)                 
                                                                            Hospital (SANTA)                                                                                                                
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                                                                            Hospital (private)            
                                                                            Hospital (tertiary)  
                                                                            Other (specify) e.g.  NGO                           
 
2.2 ACCOMPANYING REFERRAL NOTE:   Yes / No                                                                        
2.3 DURATION OF TB TREATMENT AT REFERRING FACILITY in weeks (from the 
period between the time the sputum AFB results were obtained (the patient is then put 
on TB treatment regimen) and the time the referral letter to STH was written (when the 
sputum culture result is positive) 
 
2.4 INVESTIGATION DONE to diagnose TB at referring facility: 
                                                    Laboratory alone 
                                                    Laboratory and X-Ray                                 
                                                    Clinical 
                                                     X-RAY alone 
2.5 DIAGNOSIS AT TIME OF REFERRAL:         ---------------------------------------------------- 
2.6 HIV STATUS:       Positive                      
                                   Negative                        
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                                   Unknown 
3. TREATMENT HISTORY AT SIZWE HOSPITAL 
 
3.1 MDR-TB RESISTANT TO:      ---------------------------------------------------- 
                                                   ---------------------------------------------------- 
                                                   ----------------------------------------------------- 
3.2 CONFIRMED DIAGNOSIS at STH 
                                                   ---------------------------------------------------- 
                                                   ---------------------------------------------------- 
                                                   ----------------------------------------------------- 
 
3.3 CLASSIFICATION:                       MDR-TB 
                                                            NON-MDR-TB 
 
3.4 TREATMENT RECEIVED AT SIZWE HOSPITAL:     
                                                                           -------------------------------------------------- 
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3.5 DURATION OF TREATMENT at Sizwe Hospital (refers to the period between the 
start of treatment at STH till the patient died, was discharged, or absconded):  -------------
-------------------------------- 
 
3.6 FEEDBACK NOTE from Sizwe Hospital:     Yes   / No / Unknown 
 
3.7 TYPE OF TB COMPLICATIONS: ---------------------------------------------------- 
 
3.8 MDR-TB TREATMENT OUTCOMES: 
                                      CURED 
                                      CONVERTED AT 9MONTHS                                                         
                                      COMPLETED 
                                      TREATMENT FAILURE               
                                      DEFAULT 
                                      DEATH  
                                      TRANSFER OUT 
                                      OTHER (SPECIFY):  
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